TLC599 in patients with osteoarthritis of the knee: a phase IIa, randomized, placebo-controlled, dose-finding study

Hunter, David J.; Chang, Chi-Ching; Wei, James Cheng‐Chung; Lin, Hsiao-Yi; Brown, Carl; Tai, Tien-Tzu; Wu, Ching-Yi; Chuang, Wing Chia-Ming; Shih, Sheue-Fang

doi:10.1186/s13075-022-02739-4

Cited by 22 publications

(2 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Compared to marketed FP products, plasma pharmacokinetics (PK) concentrations were in good safety margins. The assessment of efficacy displayed that EP-104IAR offered fast improvement in OA symptoms, and the effects were consistently sustained for 2–3 months across all measures ( Malone et al, 2021 ; Hunter et al, 2022 ).…”

Section: The Ia Therapy Pipelinementioning

confidence: 97%

An update on the effect of intra-articular intervention strategies using nanomaterials in osteoarthritis: Possible clinical application

Amirsaadat

Amirazad²,

Hashemihesar³

et al. 2023

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Osteoarthritis (OA) is the most common progressive condition affecting joints. It mainly affects the knees and hips as predominant weight-bearing joints. Knee osteoarthritis (KOA) accounts for a large proportion of osteoarthritis and presents numerous symptoms that impair quality of life, such as stiffness, pain, dysfunction, and even deformity. For more than two decades, intra-articular (IA) treatment options for managing knee osteoarthritis have included analgesics, hyaluronic acid (HA), corticosteroids, and some unproven alternative therapies. Before effective disease-modifying treatments for knee osteoarthritis, treatments are primarily symptomatic, mainly including intra-articular corticosteroids and hyaluronic acid, so these agents represent the most frequently used class of drugs for managing knee osteoarthritis. But research suggests other factors, such as the placebo effect, have an essential role in the effectiveness of these drugs. Several novel intra-articular therapies are currently in the clinical trial processes, such as biological therapies, gene and cell therapies. Besides, it has been shown that the development of novel drug nanocarriers and delivery systems could improve the effectiveness of therapeutic agents in osteoarthritis. This review discusses the various treatment methods and delivery systems for knee osteoarthritis and the new agents that have been introduced or are in development.

show abstract

Section: The Ia Therapy Pipelinementioning

confidence: 97%

An update on the effect of intra-articular intervention strategies using nanomaterials in osteoarthritis: Possible clinical application

Amirsaadat

Amirazad²,

Hashemihesar³

et al. 2023

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

show abstract

“…Although many nanomaterial-based drugs and nanotherapeutic strategies have been investigated for OA therapy and many clinical studies on nanotherapeutic strategies are in progress ( Dejulius et al, 2021 ; Hunter et al, 2022 ), the nanomedicines currently in clinical trials are mainly non-functional nano-scale/micron-scale materials loaded with old drugs that are already commercially available for OA therapy. They mainly extend the retention time of the drugs and reduce systemic diffusion ( Wang et al, 2021 ).…”

Section: Novel Nanotherapeutic Strategies For Oa Therapymentioning

confidence: 99%

Recent Advances in Nano-Therapeutic Strategies for Osteoarthritis

et al. 2022

View full text Add to dashboard Cite

Osteoarthritis (OA) is the most common type of arthritis and the leading cause of disability globally. It tends to occur in middle age or due to an injury or obesity. OA occurs with the onset of symptoms, including joint swelling, joint effusion, and limited movement at a late stage of the disease, which leads to teratogenesis and loss of joint function. During the pathogenesis of this degenerative joint lesion, several local inflammatory responses are activated, resulting in synovial proliferation and pannus formation that facilitates the destruction of the bone and the articular cartilage. The commonly used drugs for the clinical diagnosis and treatment of OA have limitations such as low bioavailability, short half-life, poor targeting, and high systemic toxicity. With the application of nanomaterials and intelligent nanomedicines, novel nanotherapeutic strategies have shown more specific targeting, prolonged half-life, refined bioavailability, and reduced systemic toxicity, compared to the existing medications. In this review, we summarized the recent advancements in new nanotherapeutic strategies for OA and provided suggestions for improving the treatment of OA.

show abstract

Therapeutic Controlled Release Strategies for Human Osteoarthritis

Wang,

Liu,

Venkatesan

et al. 2024

Adv Healthcare Materials

View full text Add to dashboard Cite

Osteoarthritis is a progressive, irreversible debilitating whole joint disease that affects millions of people worldwide. Despite the availability of various options (non‐pharmacological and pharmacological treatments and therapy, orthobiologics, and surgical interventions), none of them can definitively cure osteoarthritis in patients. Strategies based on the controlled release of therapeutic compounds via biocompatible materials may provide powerful tools to enhance the spatiotemporal delivery, expression, and activities of the candidate agents as a means to durably manage the pathological progression of osteoarthritis in the affected joints upon convenient intra‐articular (injectable) delivery while reducing their clearance, dissemination, or side effects. The goal of this review is to describe the current knowledge and advancements of controlled release to treat osteoarthritis, from basic principles to applications in vivo using therapeutic recombinant molecules and drugs and more innovatively gene sequences, providing a degree of confidence to manage the disease in patients in a close future.

show abstract

TLC599 in patients with osteoarthritis of the knee: a phase IIa, randomized, placebo-controlled, dose-finding study

Cited by 22 publications

References 17 publications

An update on the effect of intra-articular intervention strategies using nanomaterials in osteoarthritis: Possible clinical application

An update on the effect of intra-articular intervention strategies using nanomaterials in osteoarthritis: Possible clinical application

Recent Advances in Nano-Therapeutic Strategies for Osteoarthritis

Therapeutic Controlled Release Strategies for Human Osteoarthritis

Contact Info

Product

Resources

About